These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics. Heine H; Adanitsch F; Peternelj TT; Haegman M; Kasper C; Ittig S; Beyaert R; Jerala R; Zamyatina A Front Immunol; 2021; 12():631797. PubMed ID: 33815382 [TBL] [Abstract][Full Text] [Related]
3. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex. Mishra V; Pathak C J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849 [TBL] [Abstract][Full Text] [Related]
4. Anti-endotoxic activity and structural basis for human MD-2·TLR4 antagonism of tetraacylated lipid A mimetics based on βGlcN(1↔1)αGlcN scaffold. Garate JA; Stöckl J; Fernández-Alonso Mdel C; Artner D; Haegman M; Oostenbrink C; Jiménez-Barbero J; Beyaert R; Heine H; Kosma P; Zamyatina A Innate Immun; 2015 Jul; 21(5):490-503. PubMed ID: 25394365 [TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Kim HM; Park BS; Kim JI; Kim SE; Lee J; Oh SC; Enkhbayar P; Matsushima N; Lee H; Yoo OJ; Lee JO Cell; 2007 Sep; 130(5):906-17. PubMed ID: 17803912 [TBL] [Abstract][Full Text] [Related]
6. Ginsenoside Rh Pan S; Peng L; Yi Q; Qi W; Yang H; Wang H; Wang L Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273493 [TBL] [Abstract][Full Text] [Related]
7. Conformationally constrained lipid A mimetics for exploration of structural basis of TLR4/MD-2 activation by lipopolysaccharide. Artner D; Oblak A; Ittig S; Garate JA; Horvat S; Arrieumerlou C; Hofinger A; Oostenbrink C; Jerala R; Kosma P; Zamyatina A ACS Chem Biol; 2013 Nov; 8(11):2423-32. PubMed ID: 23952219 [TBL] [Abstract][Full Text] [Related]
8. Myeloid differentiation 2 as a therapeutic target of inflammatory disorders. Park SH; Kim ND; Jung JK; Lee CK; Han SB; Kim Y Pharmacol Ther; 2012 Mar; 133(3):291-8. PubMed ID: 22119168 [TBL] [Abstract][Full Text] [Related]
9. Two modes of ligand recognition by TLRs. Brodsky I; Medzhitov R Cell; 2007 Sep; 130(6):979-81. PubMed ID: 17889640 [TBL] [Abstract][Full Text] [Related]
10. Molecular Basis of Artemisinin Derivatives Inhibition of Myeloid Differentiation Protein 2 by Combined in Silico and Experimental Study. Qiao S; Zhang H; Sun F; Jiang Z Molecules; 2021 Sep; 26(18):. PubMed ID: 34577169 [TBL] [Abstract][Full Text] [Related]
11. Targeting myeloid differentiation 2 for treatment of sepsis. Duan G; Zhu J; Xu J; Liu Y Front Biosci (Landmark Ed); 2014 Jun; 19(6):904-15. PubMed ID: 24896325 [TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory effect of procyanidin B1 on LPS-treated THP1 cells via interaction with the TLR4-MD-2 heterodimer and p38 MAPK and NF-κB signaling. Xing J; Li R; Li N; Zhang J; Li Y; Gong P; Gao D; Liu H; Zhang Y Mol Cell Biochem; 2015 Sep; 407(1-2):89-95. PubMed ID: 26037075 [TBL] [Abstract][Full Text] [Related]